Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with empagliflozin and/or linagliptin in type 2 diabetes mellitus with metabolic fatty liver
IRCT20120215009014N601Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) comparing Metformin + empagliflozin, Metformin + linagliptin and Metformin + empagliflozin + linagliptin (3 arms). Primary endpoints: Change in liver stiffness, Change in Fibrosis Index-4 and 11 more. Started Apr 2026; status: completed.
02
Drugs
metforminempagliflozinlinagliptin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20120215009014N601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N601.